Human papillomavirus, cervical cancer prevention, and more

Vaccine

Volumn 26, Issue SUPPL. 10, 2008, Pages

  Lowy, Doug ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FALSE NEGATIVE RESULT; FEMALE; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS ONCOGENE; WART VIRUS; WOMEN'S HEALTH;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 50849124155     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.032     Document Type: Editorial

References (13)

1. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of Human Papillomavirus in Cervical Cancer: A Worldwide Perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87 11 (1995) 796-802
2. Giuliano A., Tortolero Luna G., Ferrer E., Burchell A.N., de Sanjose S., Kruger Kjaer S., et al. Epidemiology of Human Papillomavirus Infection in Men, Cancers Other Than Cervical and Benign Conditions. Vaccine 26 Suppl. 10 (2008) K16-K28
3. Parkin D.M., Louie K., and Clifford G. Burden and Trends of Type-specific Human Papillomavirus Infections and Related Diseases in the Asia Pacific Region. Vaccine 26 Suppl. 12 (2008) M1-M16
4. Parkin D.M., Almonte M., Bruni L., Clifford G.M., Curado M.P., Piñeros, et al. Burden and Trends of Type-specific Human Papillomavirus Infections and Related Diseases in the Latin America and Caribbean Region. Vaccine 26 Suppl. 11 (2008) L1-L15
5. Stanley M., Gissman L., and Nardelli-Haefliger D. Immunobiology of HPV Infection and Vaccination - Implications for Second Generation Vaccines. Vaccine 26 Suppl. 10 (2008) K61-K67
6. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A., Bruni L., de Sanjose S., et al. Epidemiology and Natural History of Human Papillomavirus Infections and Type-specific Implications in Cervical Neoplasia. Vaccine 26 Suppl. 10 (2008) K1-K15
7. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.-H., et al. Overview of Human Papillomavirus-based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. Vaccine 26 Suppl. 10 (2008) K29-K41
8. Gravitt P., Coutlée F., Iftner T., Sellors J., Quint W., et al. New Technologies in Cervical Cancer Screening. Vaccine 26 Suppl. 10 (2008) K42-K51
9. Schiller J., Castellsagué X., Villa L., and Hildescheim A. An update of Prophylactic Human Papillomavirus L1 Virus-like Particle Vaccine Clinical Trial Results. Vaccine 26 Suppl. 10 (2008) K52-K60
10. Andrus J.K., Sherris J., Fitzsimmons J., Kane M., and Aguado T. Introduction of Human Papillomavirus Vaccines into Developing Countries - International Strategies for Funding and Procurement. Vaccine 26 Suppl. 10 (2008) K87-K92
11. Andrus J.K., Lewis M., Goldie S.J., García P., Winkler J.L., Matus C.R., et al. Human Papillomavirus Vaccine Policy and Delivery in Latin America and the Caribbean. Vaccine 26 Suppl. 11 (2008) L80-L87
12. Goldie S.J., Diaz M., Constenla D., Alvis N., Andrus J.K., and Kim S.Y. Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine 26 Suppl. 11 (2008) L59-L72
13. Goldie S.J., Diaz M., Kim S.Y., Levin C., van Minh H., and Kim J. Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region. Vaccine 26 Suppl. 12 (2008) M17-M29